Category: Business

(SeaPRwire) - BEIJING, May 07, 2026 -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB17.0 million to repurchase 347,730 ordinary shares on May 6, 2026. With this latest repurchase, the Company has made repurchases on the first 4 consecutive trading days in May totaling nearly RMB100 million, and has deployed around RMB1.25 billion toward share repurchases year-to-date in 2026. This effort underscores the Company's ongoing commitment to delivering value to shareholders. CONTACT: CONTACT: PIACENTE FINANCIAL COMMUNICATIONS kanzhun@tpg-ir.com This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - BEIJING, May 07, 2026 -- KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE; HKEX: 2423), a leading integrated online and offline platform for housing transactions and services, today announced that it will report its unaudited financial results for the first quarter 2026 before the U.S. market opens on Tuesday, May 19, 2026. The Company’s management will hold an earnings conference call at 8:00 A.M. Eastern Time on Tuesday, May 19, 2026 (8:00 P.M. Beijing Time on Tuesday, May 19, 2026). For participants who wish to join the conference using dial-in numbers, please complete online registration using the link provided below at least 20 minutes prior to the scheduled call start time. Dial-in numbers, passcode and unique access PIN would be provided upon registering. Participant Online Registration: English Line: https://s1.c-conf.com/diamondpass/10054238-3nd54a.html Chinese Simultaneous Interpretation Line (listen-only mode): https://s1.c-conf.com/diamondpass/10054239-fn5s21.html A replay of the conference call will be accessible through May 26, 2026, by dialing the following numbers: United States:+1-855-883-1031Mainland, China:400-1209-216Hong Kong, China:800-930-639International:+61-7-3107-6325Replay PIN (English line):10054238Replay PIN (Chinese simultaneous interpretation line):10054239 A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://investors.ke.com. About KE Holdings Inc. KE Holdings Inc. is a leading integrated online and offline platform for housing transactions and services. The Company is a pioneer in building infrastructure and standards to reinvent how service providers and customers efficiently navigate and complete housing transactions and services in China, ranging from existing and new home sales, home rentals, to home renovation and furnishing, and other services. The Company owns and operates Lianjia, China’s leading real estate brokerage brand and an integral part of its Beike platform. With more than 24 years of operating experience through Lianjia since its inception in 2001, the Company believes the success and proven track record of Lianjia pave the way for it to build its infrastructure and standards and drive the rapid and sustainable growth of Beike. For more information, please visit: https://investors.ke.com. For investor and media inquiries, please contact: In China:KE Holdings Inc.Investor RelationsSiting LiE-mail: ir@ke.com Piacente Financial Communications Jenny CaiTel: +86-10-6508-0677E-mail: ke@tpg-ir.com In the United States:Piacente Financial Communications Brandi PiacenteTel: +1-212-481-2050E-mail: ke@tpg-ir.com This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - 25.2 cents per ADS payable on July 10, 2026TAINAN, Taiwan, May 07, 2026 -- Himax Technologies, Inc. (Nasdaq: HIMX) ("Himax" or the "Company"), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced a cash dividend of 25.2 cents per American Depositary Share (ADS), equivalent to 12.6 cents per ordinary share, for the fiscal year 2025. The cash dividend will be distributed on July 10, 2026, to shareholders of record as of June 30, 2026. The ADS book will be closed for issuance and cancellation from June 23, 2026, to June 30, 2026. Typically, Himax distributes its annual dividend around mid-year based on the previous year's financial performance. "Since our IPO in 2006, we have consistently rewarded shareholders for their ongoing commitment through our dividend policy," said Mr. Jordan Wu, President and Chief Executive Officer of Himax. "This year, we are pleased to declare an annual cash dividend of 25.2 cents per ADS, representing a payout ratio of 100.0% of last year's profit. The high payout ratio reflects our strong balance sheet and positive outlook for cash flow generation over the next few years. For business areas where we have in-house manufacturing capacity such as Wafer-Level Optics (WLO) and Liquid Crystal on Silicon (LCoS), existing capacity is in place to support the anticipated strong growth for the next few years. Himax will continue to focus on maintaining a healthy balance sheet while driving sustainable long-term growth to deliver value for our shareholders through high dividends and share repurchases," concluded Mr. Wu. About Himax Technologies, Inc. Himax Technologies, Inc. (NASDAQ: HIMX) is a leading global fabless semiconductor solution provider dedicated to display imaging processing technologies. The Company’s display driver ICs and timing controllers have been widely adopted across multiple industries worldwide, including TVs, PC monitors, laptops, mobile phones, tablets, automotive, ePaper devices, and industrial displays. As the global market share leader in automotive display technology, the Company offers innovative and comprehensive automotive IC solutions, including traditional driver ICs, advanced in-cell Touch and Display Driver Integration (TDDI), local dimming timing controllers (Local Dimming Tcon), Large Touch and Display Driver Integration (LTDI), and OLED display technologies. Himax is also a pioneer in tinyML visual-AI and optical technology related fields. The Company’s industry-leading WiseEye™ Ultralow Power AI Sensing technology, which incorporates Himax's proprietary ultralow power AI processor, always-on CMOS image sensor, and CNN-based AI algorithm, has been widely deployed in consumer electronics and AIoT-related applications. Himax optics technologies, such as diffractive wafer level optics, LCoS microdisplays, and 3D sensing solutions, are critical for enabling emerging AR/VR/metaverse technologies. Additionally, Himax designs and provides touch controllers, OLED ICs, LED ICs, EPD ICs, power management ICs, and CMOS image sensors for diverse display application coverage. Founded in 2001 and headquartered in Tainan, Taiwan, Himax currently employs approximately 2,200 people from three Taiwan-based offices in Tainan, Hsinchu, and Taipei, as well as country offices in China, Korea, and the United States. Himax holds 2,564 granted patents and has 331 pending patent applications worldwide as of March 31, 2026. http://www.himax.com.tw Forward Looking Statements Factors that could cause actual events or results to differ materially from those described in this announcement include, but are not limited to, the impact of the Covid-19 pandemic on the Company’s business; general business and economic conditions and the state of the semiconductor industry; market acceptance and competitiveness of the driver and non-driver products developed by the Company; demand for end-use application products; reliance on a small group of principal customers; the uncertainty of continued success in technological innovations; our ability to develop and protect our intellectual property; pricing pressures including declines in average selling prices; changes in customer order patterns; changes in estimated full-year effective tax rate; shortages in supply of key components; changes in environmental laws and regulations; changes in export license requirements under Export Administration Regulations (EAR); exchange rate fluctuations; regulatory approvals for further investments in our subsidiaries; our ability to collect accounts receivable and manage inventory; and other risks detailed from time to time in the Company's SEC filings, including those identified in the section titled "Risk Factors" in its Form 20-F for the year ended December 31, 2025, filed with the SEC, as may be amended. Company Contacts: Karen Tiao, Head of IR/PRHimax Technologies, Inc.Tel: +886-2-2370-3999Fax: +886-2-2314-0877Email: hx_ir@himax.com.twwww.himax.com.tw Mark Schwalenberg, DirectorInvestor Relations - US RepresentativeMZ North AmericaTel: +1-312-261-6430Email: HIMX@mzgroup.uswww.mzgroup.us This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - BEIJING, May 06, 2026 -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a prominent biopharmaceutical company specializing in cancer and autoimmune disease treatments, has announced today that the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has granted the Investigational New Drug (IND) application to launch a clinical trial for its novel CDH17-targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a critical role in tumor cell growth, migration, and metastasis. Its tumor-specific expression and functional importance in cancer biology make it an appealing and distinct target for ADC therapy, which can be developed to treat gastrointestinal cancers including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary tract cancer. Currently, there are no globally approved ADCs targeting CDH17. ICP-B208 is an innovative ADC consisting of a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house developed payload via a protease-cleavable linker. This design delivers significantly enhanced tumor-killing effects with improved stability and safety. Preclinical studies indicate that ICP-B208 exhibits strong anti-tumor activity even in tumors with low CDH17 expression, and shows better cell-killing efficacy compared to similar drugs. ICP-B208 is the second novel ADC to enter clinical development through the company’s in-house ADC platform, following ICP-B794—a novel B7-H3-targeted ADC. As the platform continues to evolve, the company is positioned to expand its portfolio with multiple differentiated ADC candidates. Dr. Jasmine Cui, Co-Founder, Chairwoman, and CEO of InnoCare, stated: “The approval of ICP-B208’s clinical trial marks another milestone in our solid tumor pipeline and validates the immense drug development potential of our ADC platform. We will continue to expand our portfolio with multiple ADC candidates and bring new hope to cancer patients worldwide.” About InnoCare Pharma InnoCare (SSE: 688428; HKEX: 9969) is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative drugs for cancers and autoimmune diseases—two therapeutic areas with unmet medical needs globally. InnoCare has established comprehensive drug discovery innovation platforms. To date, the company has built a robust product pipeline including three approved drugs (orelabrutinib, tafasitamab, and zurletrectinib), over ten innovative drug candidates in clinical development, and multiple preclinical programs. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information, visit https://www.innocarepharma.com/en or follow us on LinkedIn. InnoCare Forward-looking Statements This report contains disclosures of certain forward-looking statements. Except for factual statements, all other statements are considered forward-looking—relating to our or our management’s intentions, plans, beliefs, or expectations for future events. These statements are assumptions and estimates made by our management based on their experience, knowledge of historical trends, current conditions, expected future developments, and other relevant factors. Forward-looking statements do not guarantee future performance; actual results, developments, and business decisions may differ from the expectations outlined. Our forward-looking statements are also subject to numerous risks and uncertainties that could impact our short-term and long-term performance. Contact Media InvestorsChunhua Lu 86-10-66609879 86-10-66609999chunhua.lu@innocarepharma.com ir@innocarepharma.com This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - Hong Kong, May 06, 2026 -- NFT Ltd. (NYSE American: MI) ("Company" or "NFT", formerly known as Takung Art Co., Ltd.), an emerging online trading platform operator of international art and collectibles, today announced that its board of directors approved a 1-for-80 reverse share split of its Class A and Class B ordinary shares on April 23, 2026, following shareholder approval on April 17, 2026 of a reverse split at a ratio of up to 1-for-200. The reverse split is expected to become effective on or about May 18, 2026 (the “Reverse Split”). Upon the effectiveness of the Reverse Split, NFT shareholders will receive one new ordinary share of NFT for every eighty shares they hold. NFT’s Class A ordinary shares are expected to begin trading on a split-adjusted basis when the market opens on May 18, 2026. Following the Reverse Split, the Class A and Class B ordinary shares will have a new par value of $0.04 per share. The Class A ordinary shares will continue to trade on the NYSE American under the symbol “MI” with the new CUSIP number, G6363T123. The Reverse Split is expected to lead NFT’s Class A ordinary shares to trade at approximately eighty times the price per share at which it trades prior to the effectiveness of the Reverse Split. NFT, however, cannot assure that the price of its Class A ordinary shares after the Reverse Split will reflect the 1 for 80 Reverse Split ratio, that the price per share following the effective time of the Reverse Split will be maintained for any period of time, or that the price will remain above the pre-split trading price. NFT's Articles and Memorandum of Association were amended and restated in connection with the Reverse Split. As of May 6, 2026, there were approximately 18,478,875 of NFT's Class A ordinary shares and 0 of NFT’s Class B ordinary shares outstanding. Effecting the Reverse Split will reduce that amount to approximately 230,986 Class A ordinary shares and 0 Class B ordinary shares outstanding. Treatment of Stock Options and Restricted Shares The number of ordinary shares into which NFT's outstanding stock options and restricted shares, as well as the options' relevant exercise price per share, will be proportionally adjusted to reflect the Reverse Split. The number of shares authorized for issuance under NFT's equity incentive plans will also be proportionally reduced to reflect the Reverse Split. Fractional Shares Any fractional shares that would have resulted because of the Reverse Split will be rounded up to the nearest whole share. New Ordinary Share Certificates NFT will adopt a new share certificate in connection with the implementation of the reverse share split. NFT's transfer agent, VStock Transfer LLC, will manage the exchange of share certificates. Shareholders of record will receive a letter of transmittal providing instructions for the exchange of their old certificates as soon as practicable following the effectiveness of the Reverse Split. Shareholders should not send in their old stock certificates until they receive a letter of transmittal from VStock Transfer LLC. Shareholders who hold their shares through a securities broker or nominee (i.e., in "street name") will be contacted by their brokers or nominees with any instructions. For more information, shareholders and securities brokers should contact VStock Transfer LLC at 212-828-8436. About NFT Limited NFT Limited (formerly known as Takung Art Co Ltd.) operates an online electronic platform (www.nftoeo.com) for offering and trading of digital artwork. Through its platform, the Company allows artists/art dealers/owners to access a much bigger art trading market where they can engage with a wide range of investors. It generates revenue in the form of services in connection with the offering and trading of artwork on its platform, primarily consisting of listing fees, trading commissions, and management fees. Please visit: www.nftoeo.com. Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Federal Securities Act, including but not limited to our expectations of future financial performance, business strategy or business. These statements constitute forecasts, prospects and forward-looking statements and are not performance guarantees. NFT warns that forward-looking statements are subject to many assumptions, risks and uncertainties that will change over time. Forward looking statements may be identified by words such as "may", "can", "should", "will", "estimate", "plan", "project", "forecast", "intend", "expect", "predict", "believe", "seek", "target", "Outlook" or similar words. These forward-looking statements are based on information available as of the date of this press release and our management's current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk factors described by NFT in its filings with the Securities and Exchange Commission ("SEC"). SOURCE NFT Contact: Investor RelationsIR@nft-limited.com This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - DOVER, USA, May 06, 2026 -- E-Power Inc. (“E-Power”, the “Company”, “we” or “our”) (NASDAQ: EPOW), a leading provider of AI Data Center (AIDC) microgrid solutions and advanced battery materials, today announced a key milestone in its North American expansion following the signing of a landmark three-phase Microgrid Construction & Services Agreement with ZL Bio LLC. Located in Middletown, California, this project marks a significant advancement in deploying large-scale, resilient energy infrastructure for industrial-grade cultivation operations. A Scalable Breakthrough in Energy Infrastructure This agreement establishes a comprehensive roadmap to scale ZL Bio’s power capacity from 3 MW to 50 MW, utilizing an advanced “Solar + Storage + Backup” framework. This strategic structure enables seamless expansion across three development phases, ensuring energy supply aligns perfectly with the operational growth of ZL Bio’s 6,000-unit greenhouse facility. Phase 1 (3 MW): Immediate mobilization to power 330 greenhouse units with a capital expenditure (CAPEX) of $15.12 million.Phase 2 (+6 MW): Incremental scale-up to 9 MW cumulative capacity serving 997 units, valued at $30.24 million.Phase 3 (+41 MW): A large-scale industrial expansion to 50 MW serving 6,000 units, bringing total project CAPEX to approximately $252 million. Technical Excellence and Unmatched Reliability Per the terms of the EPC (Engineering, Procurement, and Construction) agreement, E-Power will deliver a turnkey microgrid solution featuring Tier-1 bifacial solar modules and high-safety Lithium Iron Phosphate (LFP) Battery Energy Storage Systems (BESS). Key technical breakthroughs for this project include: Instantaneous Islanding: The system is engineered to detect grid disturbances and switch to “island mode” within 20ms, ensuring zero downtime for critical environmental control systems.Intelligent Energy Management: Deployment of a proprietary EMS/SCADA platform for 24/7 remote monitoring, automated load shedding, and demand response initiatives.Guaranteed Performance: E-Power has committed to a 99.5% system availability guarantee and a financially secure solar yield protection plan. Management Commentary "This $252 million agreement marks a major breakthrough for E-Power as we solidify our position as a premier provider of mission-critical energy infrastructure in the United States," said Mr. Haiping Hu, Chairman of E-Power Inc. "By addressing ZL Bio’s complex energy needs with our integrated microgrid technology, we are demonstrating that E-Power can deliver the scale, reliability, and technical sophistication required by the next generation of high-demand industrial and AI-driven enterprises." Long-Term Operations and Maintenance In addition to construction, the partnership includes a long-term Operations & Maintenance (O&M) commitment. E-Power will provide 24/7 remote monitoring, quarterly technical inspections, and a high-priority Emergency Response Service Level Agreement (SLA) to maintain maximum uptime for the facility. About E-Power Inc. E-Power Inc., through its joint venture, manufactures and sells graphite anode material for lithium-ion batteries. The company’s joint venture has completed construction of a manufacturing facility with a production capacity of 50,000 tons. This plant runs on low-cost renewable electricity, which allows E-Power to be a low-cost and low–environmental-impact producer of graphite anode material. Mr. Haiping Hu, the company’s founder and CEO, has been a leading pioneer in the global graphite anode industry since 1999. The company’s management team is also composed of experts with years of experience and strong track records of success in the graphite anode sector. For further information, please visit the company’s website at www.sunrisenewenergy.com. Forward-looking statement Certain statements in this press release regarding the company’s future expectations, plans and prospects constitute forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include references to plans, goals, objectives, strategies, future events, expected results, assumptions and any other unfulfilled factual statements. Any wording using terms such as “may”, “will”, “want”, “should”, “believe”, “expect”, “anticipate”, “estimate” or similar non-factual phrasing will be classified as forward-looking statements. A variety of factors may cause actual results to differ materially from historical results or the projections outlined in these forward-looking statements. These factors include, but are not limited to, the company’s strategic objectives, future business plans, market demand and user adoption of the company’s products or services, technological updates, economic trends, the company’s reputation and brand, the impact of industry competition, applicable policies and regulations, China's macroeconomic conditions, international market conditions, and other associated risks and assumptions. Given these and other related factors, we advise investors not to blindly rely on these forward-looking statements, and urge investors to visit the SEC’s website to review the company’s relevant filings for additional factors that may impact the company’s future operating results. The company has no obligation to publicly update or revise these forward-looking statements to reflect new events or circumstances unless required by law. For further information, please contact: The Company: IR Department Email: IR@sunrisenewenergy.com Phone: +1 4084890472 This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - Hong Kong/New York, May 6, 2026 — Trollee Holdings Limited, a pioneer in AI-driven smart retail solutions, and AIMO Holdings Limited, a Hong Kong-based commercial robotics firm, announced today that they have signed a Merger Framework Agreement. The combined entity will integrate smart retail technology with autonomous robotics to deliver end-to-end intelligent automation services for retail, commercial facilities, smart cities, and environmental monitoring. The transaction forms a unified platform covering two strategic layers: Smart Retail & In-Store AI (Trollee): Trollee provides AI-powered smart shopping carts, real-time customer analytics, edge-based intelligent advertising, and seamless checkout solutions to major retail chains across Asia and Europe. Autonomous Robotics (AIMO): AIMO designs AI-driven outdoor patrol robots for shopping malls, property and facility management, public safety, and open-area surveillance—with flagship models purpose-built for real-world commercial environments. “We are merging two complementary technology forces into one,” said Thim S Chiew, Global CEO of Trollee Holdings Limited. “Trollee brings the retail intelligence layer that understands customers and optimizes operations. AIMO contributes the physical autonomous presence that acts on those insights—from automated security and inventory monitoring to customer assistance inside and outside the store. Together, we have a complete retail automation stack.” The merger capitalizes on multiple high-growth verticals where retail intelligence and robotics intersect: Vertical Synergy Smart Retail: Trollee’s in-store AI paired with AIMO’s facility patrol robots for automated security, inventory monitoring, and customer assistance. Smart Cities & Public Spaces: AIMO’s autonomous patrol robots for surveillance, hazard detection, and facility management, enhanced by Trollee’s edge-based customer analytics for retail-adjacent public areas. Environmental Monitoring: AIMO’s outdoor autonomous platforms for remote data collection, combined with Trollee’s real-time sensing capabilities. Commercial Facilities & Logistics: AIMO’s custom robotic solutions for property management and security, integrated with Trollee’s asset tracking and smart retail platform. “The retail industry is shifting toward AI-driven, frictionless experiences, and Trollee is at the forefront,” said Ricky Lei of AIMO. “By joining forces with AIMO’s autonomous robotics, we extend that intelligence beyond the shopping cart to the entire physical environment of the store, parking lot, and surrounding facility. This merger creates a seamless loop of data, insight, and action.” Transaction Terms & Listing Plans The merger framework agreement has been signed. Following the completion of the merger, the combined company intends to pursue a listing on the Nasdaq Stock Market, either through a direct listing or a reverse takeover (RTO) of an existing publicly traded entity. The parties are evaluating the most efficient path to become a publicly traded company while continuing to execute their integrated business strategy. The merged company will operate across North America, Greater China, Southeast Asia, Japan, South America, the Middle East, and South Africa, leveraging Trollee’s established retail footprint across Asia and Europe, and AIMO’s strong presence in the Hong Kong and Asia-Pacific robotics market, with accelerated expansion into these newly added high-growth regions. “Our vision is an intelligent, autonomous retail ecosystem where real-time data and physical robotics work in harmony,” said Ricky Lei. “This merger creates a leader positioned to define the future of smart spaces, and our planned Nasdaq listing will provide the platform to accelerate that vision globally.” About Trollee Holdings Limited Trollee Holdings Limited is a leading smart retail technology company revolutionizing the retail experience with AI-powered smart shopping carts, edge-based customer analytics, intelligent advertising, and frictionless checkout. The company partners with major retail chains across China, Hong Kong (China), Singapore, Thailand, Malaysia, France, and is expanding into Japan, South America, the Middle East, and South Africa. About AIMO AIMO is a Hong Kong-based robotics company specializing in AI-driven autonomous mobile platforms for outdoor commercial environments. Its flagship models are purpose-built for shopping mall management, public security and surveillance, property and facility management, and open-area patrolling, with bespoke solutions tailored to enterprise needs. AIMO is actively deploying its solutions across Asia and entering new markets including Japan, South America, the Middle East, and South Africa. Forward-Looking Statements This press release contains forward-looking statements regarding the proposed merger and the combined company’s future performance, including its intention to list on Nasdaq via direct listing or RTO. Actual results may differ due to customary closing conditions, regulatory approvals, market conditions, and other factors. There is no assurance that the merger will be completed on the terms described or at all, or that any listing will occur. Media Contact: Mr. Ricky Lee Email: info@aimo.ai This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - The earnings call is scheduled for 8:30 a.m. Eastern Time on Wednesday, May 13, 2026.HONG KONG, May 6, 2026 -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, announced today that it will release its unaudited financial results for the first quarter ended March 31, 2026, prior to the opening of U.S. markets on Wednesday, May 13, 2026. The company’s management will host a conference call to discuss the results at 8:30 a.m. U.S. Eastern Time / 8:30 p.m. Hong Kong Time on the same day. To participate in the call, listeners can dial in using the following numbers: International:617-3145-4010US/Canada (Toll Free):1-855-881-1339UK (Toll Free):0-800-051-8245Mainland China (Toll Free):4001-200-659Hong Kong (Toll Free):800-966-806Singapore (Toll Free):800-101-2785 Participants are advised to dial in at least 10 minutes before the scheduled start time and request to be connected to the call for “UCLOUDLINK GROUP INC.” A live and archived webcast of the conference call will also be accessible at https://ir.ucloudlink.com. A telephone replay will be available one hour after the end of the conference until May 20, 2026, by dialing: US/Canada (Toll Free):1855-883-1031International:617-3107-6325Replay Passcode:10054677 About UCLOUDLINK GROUP INC.UCLOUDLINK is the world’s first and leading mobile data traffic sharing marketplace, pioneering the sharing economy business model for the telecommunications industry. The Company’s products and services deliver unique value propositions to mobile data users, handset and smart-hardware companies, mobile virtual network operators (MVNOs) and mobile network operators (MNOs). Leveraging its innovative cloud SIM technology and architecture, the Company has redefined the mobile data connectivity experience by allowing users to access mobile data traffic shared by network operators on its marketplace, while providing reliable connectivity, high speeds and competitive pricing. For more information, please contact: UCLOUDLINK GROUP INC.Investor Relations: Christensen AdvisoryDaniel GaoChristian Arnell, Managing DirectorTel: +852-2180-6111Tel: +852-2117-0861E-mail: ir@ucloudlink.comE-mail: ucloudlink@christensencomms.com This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - NEW YORK, May 06, 2026 -- Pony AI Inc. (“Pony.ai” or the “Company”) (NASDAQ: PONY; HKEX: 2026), a global leader in achieving large-scale mass production and commercialization of autonomous driving technology, today announced that it will report its unaudited financial results for the first quarter of 2026 before the U.S. market opens on Tuesday, May 26, 2026. The Company’s management will hold an earnings conference call on Tuesday, May 26, 2026, at 8:00 A.M. Eastern Time in the United States or 8:00 P.M. Beijing/Hong Kong Time on the same day. Participants who wish to join the call by phone are required to complete the online registration process using the link provided below prior to the scheduled start time of the call. Upon registration, participants will receive a confirmation email containing dial-in numbers, passcode, and a unique access PIN. Participant Online Registration: https://dpregister.com/sreg/10208868/103f733bea8 A replay of the conference call will be accessible through June 2, 2026, by dialing the following numbers: United States: 1-855-669-9658International: 1-412-317-0088Replay Access Code: 2939290 A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.pony.ai. About Pony AI Inc. Pony AI Inc. (NASDAQ: PONY; HKEX: 2026), founded in 2016, is a global leader in achieving large-scale mass production and commercialization of autonomous driving technology. Pony.ai is committed to delivering safe, advanced, and reliable autonomous driving technology and solutions. At the heart of Pony.ai’s strategy is its proprietary world model PonyWorld and its Virtual Driver technology. Together, they power the development and scaling of its Robotaxi services, Robotruck services, and licensing and applications businesses. With operations spanning China, Europe, East Asia, the Middle East, and beyond, Pony.ai stands among a select few companies globally to achieve fully driverless commercial operations. Pony.ai has forged deep and extensive partnerships across the autonomous driving value chain, enabling it to accelerate the commercialization of autonomous driving in line with its ultimate vision: “Autonomous Mobility Everywhere.” For more information, please visit: https://ir.pony.ai. For investor inquiries, please contact: Pony.aiInvestor RelationsEmail: ir@pony.ai This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - GEORGE TOWN, Cayman Islands, May 06, 2026 -- Toobit, the award-winning global cryptocurrency exchange, today announces the publication of its latest Proof of Reserves (PoR) report, independently verified by Hacken. The comprehensive assessment by Hacken confirms that Toobit maintains a collateral ratio of over 100% across all in-scope digital assets, including BTC, ETH, USDT, and USDC. This independent audit verifies a safe 1:1+ backing for every trader deposit, with findings confirming a reserve surplus that ensures all trader liabilities are fully over-collateralized. In addition, the verification process validated the individual balances of over 640,000 accounts. This was achieved by cross-referencing internal data against legal documentation and official statements from third-party institutional custodians to ensure the highest level of accuracy. To provide full transparency, Hacken employed a multi-stage methodology focused on three key stages. First, auditors performed a Proof of Liabilities by verifying the total balances of over 600,000 liability holders to ensure an accurate representation of client deposits. The second stage involved Asset Verification, where auditors compared total reserve balances against the client liability report to confirm full coverage. Finally, the process included Operational Oversight to review information flow and custodial reporting, ensuring all data remained authentic and unaltered. In tandem with these audit results, Toobit has launched an upgraded Proof of Reserves page, moving beyond static reporting to a dynamic transparency model. This hub enables traders to monitor live reserve ratios for major tokens and access historical audit data through a user-friendly interface. Central to this portal is the integration of Merkle tree technology. By consolidating trader balances into a singular, secure Merkle root hash, Toobit provides a transparent, tamper-proof method for individuals to verify that their specific account balance was included in the audit. This cryptographic proof ensures accountability while maintaining privacy for all traders. The full audit report is available for public review. Detailed documentation regarding the audit scope, methodology, and technical findings can be found on Hacken's official website. Cryptocurrency exchanges have entered a maturation phase driven by independent verification. Industry leaders maintain reserve coverage ratios between 124% and 125%, far exceeding the 100% safety benchmark. As frameworks like MiCA intensify supervision, long-term operational stability is defined by "compliance by design," integrating Proof of Reserves and transparent disclosures into core infrastructure. About Toobit Toobit is where the future of crypto trading unfolds—an award-winning cryptocurrency derivatives exchange built for those who thrive exploring new frontiers. With deep liquidity and cutting-edge technology, Toobit provides traders worldwide with a fair, secure, and transparent environment to navigate digital asset markets. The exchange offers a Broker Program with direct API integration for leading platforms including CCXT, Altrady, and CryptoCopy. As the Official Regional Partner of LALIGA, Toobit gives traders the opportunity to play on a bigger stage and discover what's next. For more information about Toobit, visit: Website | X | Telegram | LinkedIn | Discord | Instagram Contact: Davin C. Email: market@toobit.com Website: www.toobit.com This sponsored content is provided by the content provider and does not necessarily reflect the views of this media platform or its publisher. The information is shared for general informational purposes only and should not be considered financial, investment, or trading advice. Cryptocurrency and mining-related activities carry risks, including the potential loss of capital, and readers are encouraged to conduct their own research and seek professional advice where appropriate. Speculate only with funds that you can afford to lose. The media platform and publisher assume no responsibility for any losses or claims arising from reliance on this content. GlobeNewswire does not endorse any content on this page. Legal Disclaimer: This article is provided on an “as-is” basis, without warranties or representations of any kind, express or implied. The media platform assumes no responsibility or liability for the accuracy, content, completeness, legality, or reliability of the information presented. Any complaints, claims, or copyright concerns related to this article should be directed to the content provider mentioned above. This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - NANJING, China, May 05, 2026 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) announced today that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has identified Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the initial three priority indications for the clinical advancement of LBL-047 (branded as DNTH212 outside Greater China). Strategic Focus: Moving Forward with LBL-047 Clinical Development LBL-047 is a potential first- and best-in-disease bifunctional fusion protein designed to target plasmacytoid dendritic cell (pDC) BDCA2 to decrease Type 1 interferon production, while concurrently blocking BAFF/APRIL to inhibit B cell function. By addressing both the innate and adaptive immune systems, this complementary and distinct approach offers the potential to treat multiple autoimmune conditions with enhanced therapeutic outcomes. Treating LBL-047 as a key pipeline asset and strategic focus, Dianthus is progressing the clinical development of LBL-047 in SjD, SLE, and DM — three areas characterized by high unmet medical needs. Following an upsized underwritten public offering in March 2026, Dianthus raised approximately $719 million in gross proceeds, creating a solid financial base to fund the global development of LBL-047. Phase 1 Results Expected in 2H’26 A two-part Phase 1 study was launched in China in December 2025, enrolling healthy volunteers (Part A) and SLE patients (Part B), with top-line data from the healthy volunteer group expected in the second half of 2026. After the Phase 1 study concludes, Dianthus intends to announce the next steps for the clinical progression of its prioritized indications. About LBL-047LBL-047 is a bifunctional fusion protein consisting of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and an engineered transmembrane activator and CAML interactor (TACI) ectodomain. Its mechanism involves selectively depleting pDCs to lower type 1 interferon levels, while simultaneously inhibiting B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) signaling pathways to curb B-cell activation, differentiation, and antibody generation. By targeting two critical factors in autoimmune disease pathology, this differentiated approach holds promise for treating various autoimmune indications. Moreover, LBL-047 features Fc engineering to prolong its half-life, enabling a convenient subcutaneous self-administration regimen with a dosing frequency of Q4W or less, which supports its potential as a first-line biologic therapy. On October 16, 2025, Leads Biolabs secured an exclusive global partnership with Dianthus, a clinical-stage biotechnology company focused on developing next-generation treatments for severe autoimmune diseases, with the total potential deal value estimated at up to $1 billion. According to the agreement, Dianthus obtained exclusive global rights to research, develop, manufacture, and commercialize LBL-047 outside Greater China, where it is designated as DNTH212, collaborating to advance its global development and maximize clinical and commercial value. About Leads BiolabsEstablished in 2012, Leads Biolabs is a clinical-stage biotechnology entity committed to the identification, creation, and commercialization of cutting-edge therapies to meet unaddressed medical necessities in oncology, autoimmune diseases, and other serious conditions within China and internationally. We stand at the forefront of next-generation immuno-oncology therapies, boasting a diverse pipeline of 14 novel drug candidates, which includes four in clinical stages and one in the registration stage. We utilize a science-centric R&D methodology and have built extensive R&D competencies covering antibody discovery and engineering, in vivo and in vitro efficacy testing, and druggability analysis. Additionally, we have created several proprietary technology platforms, such as the LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), and TOPiKinectics (ADC platform). These platforms form the foundation of our ongoing innovation and are confirmed by the clinical data from our bispecific antibody portfolios. We have built integrated strengths spanning early discovery, translational medicine, clinical trials, CMC, and business development. The inventive character and competitive edge of our drug candidates, combined with our international outlook, forward-thinking strategy, and rapid clinical validation, have established us as a sought-after partner for top-tier industry entities and investment groups. For further details, please visit https://en.leadsbiolabs.com/ CONTACT: Contact: yizi@leadsbiolabs.com This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - NANJING, China, May 05, 2026 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) announced today that its collaborator, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has designated Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the initial three priority indications for the clinical development of LBL-047 (referred to as DNTH212 outside Greater China). Strategic Priority: Advancing Clinical Development of LBL-047 LBL-047 is a bifunctional fusion protein with the potential to be first- and best-in-disease. It targets plasmacytoid dendritic cell (pDC) BDCA2 to lower Type 1 interferon production, while also inhibiting BAFF/APRIL to curb B cell function. This dual-targeted, complementary strategy engages both the innate and adaptive immune systems, offering a differentiated approach that could lead to better outcomes across multiple autoimmune conditions. As a core asset in its pipeline and a key strategic focus, Dianthus is progressing the clinical development of LBL-047 in SjD, SLE, and DM—three disease areas with significant unmet medical needs. To support the global development of LBL-047, Dianthus secured a strong financial base by completing an upsized underwritten public offering in March 2026, which generated gross proceeds of approximately $719 million. Phase 1 Data Anticipated in 2H’26 A two-part Phase 1 study commenced in China in December 2025, enrolling healthy volunteers (Part A) and patients with SLE (Part B). Top-line results from the healthy volunteer cohort are anticipated in the second half of 2026. Following the conclusion of the Phase 1 trial, Dianthus intends to announce an update on the subsequent steps for progressing its prioritized indications in clinical development. About LBL-047LBL-047 is a bifunctional fusion protein consisting of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and an engineered transmembrane activator and CAML interactor (TACI) ectodomain. Its mechanism is designed to selectively deplete pDCs, thereby reducing type 1 interferon production, while concurrently blocking the B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) signaling pathways to inhibit B-cell activation, differentiation, and antibody production. This distinct strategy, which addresses two primary drivers of autoimmune disease pathogenesis, holds promise for treating a range of autoimmune indications. Furthermore, Fc engineering has been used to optimize LBL-047, prolonging its half-life and enabling the potential for a patient-friendly, subcutaneous self-administration regimen with a dosing frequency of once every four weeks (Q4W) or less, bolstering its profile as a potential first-line biologic therapy. On October 16, 2025, Leads Biolabs formed an exclusive global partnership with Dianthus, a clinical-stage biotechnology company focused on creating next-generation treatments for severe autoimmune diseases. The total potential value of the agreement is up to $1 billion. As per the terms, Dianthus received exclusive global rights to research, develop, manufacture, and commercialize LBL-047 outside Greater China, under the name DNTH212. The two companies are working together to advance the global development of the asset to maximize its clinical and commercial potential. About Leads BiolabsEstablished in 2012, Leads Biolabs is a clinical-stage biotechnology company committed to discovering, developing, and commercializing novel therapies to meet unmet medical needs in oncology, autoimmune disorders, and other serious diseases in China and worldwide. The company is a leader in next-generation immuno-oncology, with a differentiated portfolio of 14 innovative drug candidates. This pipeline includes four clinical-stage candidates and one asset in the registration stage. Leads Biolabs employs a science-driven R&D model and has built extensive capabilities covering antibody discovery and engineering, in vivo and in vitro efficacy evaluation, and druggability assessment. The company has also created several proprietary technology platforms, such as the LeadsBody platform (a CD3 T-cell engager platform), the X-body platform (a 4-1BB engager platform), and TOPiKinectics (an ADC platform). These platforms form the foundation for ongoing innovation and their effectiveness has been demonstrated by the clinical results from the company's bispecific antibody portfolios. The company possesses integrated capabilities across early discovery, translational medicine, clinical development, CMC, and business development. The innovative quality and competitive advantages of its drug candidates, along with its global outlook, proactive strategy, and efficient clinical validation, have positioned Leads Biolabs as an attractive partner for top-tier industry players and investment institutions. Additional information is available at https://en.leadsbiolabs.com/ CONTACT: Contact: yizi@leadsbiolabs.com This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - WUHU, China, May 05, 2026 -- From April 20 to 26, LEPAS made a striking appearance in Milan under the theme “Here’s to Elegance,” marking its European regional brand debut. Following the European Regional Brand Technology Unveil on April 20, the six-day public exhibition (April 21–26) welcomed global visitors to an immersive brand experience that seamlessly blended aesthetics, technology, and lifestyle. Held during Milano Design Week, the showcase attracted designers, fashion insiders, and industry professionals, generating strong foot traffic and social engagement. As a global design capital, Milan provided the ideal stage for LEPAS’s European debut. Located in Tortona, the core exhibition district of Milano Design Week, the LEPAS space featured a minimalist, contemporary design language, combining artistic ambiance with advanced technology to create a premium, immersive environment. Visitors experienced a multi-sensory journey that reflected the brand’s vision of elegant mobility. LEPAS curated a refined on-site experience, including live string performances and harp recitals that enhanced the atmosphere with elegance and calm. In collaboration with De’Longhi, a dedicated coffee tasting area allowed guests to enjoy Italian coffee culture alongside the exhibition. Together, these elements expressed LEPAS’s vision of a composed, sophisticated lifestyle aligned with the expectations of a quality-driven global audience. At the center of the exhibition, the LEPAS L6 — making its European debut — was presented alongside the flagship LEPAS L8. Both models embody the brand’s exploration of elegant mobility across different scenarios. The L6 integrates European minimalism with refined Eastern aesthetics through the “Leopard Aesthetics” design language. Its dynamic exterior lines and a wraparound smart cockpit with a “Skyline” theme and central waterfall display create a spacious, tranquil premium interior. Every detail reflects the expectations of European high-end users for both quality and lifestyle sophistication. Built on the Intelligent LEX Platform, LEPAS brings its concept of “Elegant Technology” to life. With multi-power compatibility and adaptability to global markets, the platform transforms advanced new energy and intelligent technologies into a smooth, quiet, and refined driving experience — making technology a natural extension of everyday life. Visitors from around the world experienced the brand firsthand, noting that LEPAS redefines traditional perceptions of new energy vehicles by balancing elegant design with advanced technology. European fashion influencers and automotive KOLs widely attended the event, reinforcing the brand’s resonance with the premium market. As a global new energy brand under Chery Group, LEPAS continues to expand its presence in Europe. The flagship LEPAS L8 has been showcased at the Turin Auto Show and participated in media test drives in markets such as Spain. At Auto China 2026, LEPAS also unveiled its global NEV strategy and product lineup, including the LEPAS L6 EV, LEPAS L4 EV, and LEPAS L6 PHEV, alongside its Global Partner Conference to strengthen international collaboration. Starting from Milan, LEPAS will continue to use design as its language and technology as its foundation, delivering refined new energy mobility solutions for global users. Chery Group Peiwen Tan Email: tanpeiwen@mychery.com Website: lepasinternational.com Dateline: Wuhu Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0caa113a-998f-426a-b293-d3c79627c028https://www.globenewswire.com/NewsRoom/AttachmentNg/e1a74f5d-5aa2-4c69-96d7-e9ff7956fa74 This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.

(SeaPRwire) - WUHU, China, May 05, 2026 -- On April 24, Auto China 2026 officially opened. Chery Group’s booth, positioned at the forefront of global mobility, welcomed more than 4,000 guests from over 100 countries, setting new records for scale and participation. On this global stage, LEPAS, Chery Group’s all-new premium NEV brand, made its debut under the theme “Elegance Moves the World”. The brand unveiled its NEV strategy and introduced its product lineup, including the LEPAS L6 EV, LEPAS L4 EV, and LEPAS L6 PHEV—marking the launch of its “Year of Delivery” across brand, product, and global network. At the press conference, Yin Tongyue, Chairman of Chery Automobile Co., Ltd., emphasized long-term vision, world-class quality, and global partnership. Zhang Guibing, Executive Vice President of Chery Auto and President of Chery International, highlighted that participation of over 4,000 partners reflects global trust and will continue to drive smarter, greener mobility worldwide. As the NEV market shifts to value-driven growth, users seek more refined, human-centered experiences. LEPAS responds as the Preferred Brand for Elegant Mobility Life, elevating NEV from a technology race to a lifestyle choice—turning every journey into a confident, effortless experience. Zhai Xiaobing, CEO of LEPAS, noted mobility should be easier, technology more intuitive, and life more relaxed. Backed by Chery’s global R&D network, LEPAS is built on three pillars—Leopard Aesthetics, Exquisite Space, and Elegant Technology—bringing “elegance” into a tangible, user-focused experience. Built on the LEX intelligent NEV platform, LEPAS has developed a structured portfolio centered on the L4, L6, and L8. At Auto China 2026, three models were introduced to meet diverse needs—from urban commuting to long-distance travel. The LEPAS L6 EV is designed for urban mobility, featuring a low, wide stance, signature lighting, and technologies including VPD, H-NOA, Bosch IPB 2.0, and an AI Agent. Its cockpit integrates ambient lighting, fragrance, and drive modes to create a responsive, comfortable environment. The LEPAS L4 EV targets urban use with dynamic styling, 160kW power, multi-link suspension, and 21 ADAS and connectivity features. With a 500 km-class range and fast charging, it balances daily commuting with weekend travel. The LEPAS L6 PHEV offers versatility for city and long-distance driving, combining extended range with the brand’s design language and platform tuning. It delivers an “anxiety-free” driving experience and will begin global validation through the LEPAS Global Journey of Elegant Driving. Together, these models reflect LEPAS’s philosophy: “Good-looking, Fun, Practical, and Enjoyable.” The brand plans to launch 10 NEV models over the next three years. Five days before the show, LEPAS made its European debut at Milan Design Week. From April 26 to 28, the LEPAS Global Partner Conference will further accelerate its Year of Delivery. From brand vision to global rollout, LEPAS demonstrates that elegance is more than a concept—it’s a mobility experience users can truly feel and choose. Chery GroupPeiwen TanEmail: tanpeiwen@mychery.comWebsite: lepasinternational.comCity: Wu Hu Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ce2c94c8-427c-4807-8eb0-c5dc6625090d https://www.globenewswire.com/NewsRoom/AttachmentNg/e6d9d8d5-f1b5-4600-a92c-28a7c544251d https://www.globenewswire.com/NewsRoom/AttachmentNg/9f40bc16-38bc-47bd-ae0c-d93bb7aa3bb2 https://www.globenewswire.com/NewsRoom/AttachmentNg/d607b7ba-26f1-43cf-abfd-12f4df2f27d6 https://www.globenewswire.com/NewsRoom/AttachmentNg/14122a56-ca16-4d7a-a2dd-4eff0527598b https://www.globenewswire.com/NewsRoom/AttachmentNg/3f25d92d-3878-461b-a2f1-15c99a86573d This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.